Focused On-demand Library for Zinc finger protein ZFPM2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8WW38

UPID:

FOG2_HUMAN

Alternative names:

Friend of GATA protein 2; Zinc finger protein 89B; Zinc finger protein multitype 2

Alternative UPACC:

Q8WW38; Q32MA6; Q9NPL7; Q9NPS4; Q9UNI5

Background:

Zinc finger protein ZFPM2, also known as Friend of GATA protein 2, plays a pivotal role in heart morphogenesis and the development of coronary vessels. It functions as a transcription regulator by forming a heterodimer with GATA family transcription factors, influencing gene expression essential for cardiogenesis. Additionally, ZFPM2 is implicated in gonadal differentiation, potentially through the regulation of SRY expression.

Therapeutic significance:

Given its involvement in critical congenital heart anomalies such as Tetralogy of Fallot, Diaphragmatic hernia 3, 46,XY sex reversal 9, and Conotruncal heart malformations, ZFPM2 presents a promising target for therapeutic intervention. Understanding the role of Zinc finger protein ZFPM2 could open doors to potential therapeutic strategies for these complex conditions.